Phio Pharmaceuticals Corp.
PHIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001533040
In the last 90 days, Phio Pharmaceuticals Corp. insiders filed 5 open-market purchases and 0 sales; 24 institutions reported holding it in 13F filings for Q2 2026, worth $662.6K in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Phio Pharmaceuticals Corp. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 6 | 11 | +5 |
| Shares | 28.5K | 154.0K | +125.5K (+440.4%) |
| Value | $98.3K | $277.4K | +$179.1K (+182.1%) |
New holders (7)
Institutions that held Phio Pharmaceuticals Corp. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 44,526 | $80.1K | 0.00% |
| HRT Financial LP | 42,338 | $76.0K | 0.00% |
| Virtu Financial LLC | 40,910 | $74.0K | 0.00% |
| Cetera Investment Advisers | 13,000 | $23.4K | 0.00% |
| Morgan Stanley | 5,911 | $10.6K | 0.00% |
| Barclays PLC | 203 | $365 | 0.00% |
| SBI Securities Co., Ltd. | 63 | $113 | 0.00% |
Sold out (2)
Institutions that held Phio Pharmaceuticals Corp. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Sabby Management, LLC | 25,131 | $86.7K |
| Nordwand Advisors, LLC | 500 | $1.73K |